Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 7Phase 3 4Phase 1/2 4Phase 2/3 2

Status

Completed 3Terminated 1

Sponsor Class

NETWORK 7OTHER 4NIH 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 290Prostatic Neoplasms 192Neoplasm Metastasis 154Multiple Myeloma 147Colorectal Neoplasms 123Lung Neoplasms 104Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 88Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 80Stomach Neoplasms 76Small Cell Lung Carcinoma 72Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 66Pain 66Uterine Cervical Neoplasms 64Carcinoma, Renal Cell 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

Trabectedin 2olaratumab 1milademetan 1brigimadlin 1Doxorubicin 1Dacarbazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Liposarcoma × Clear all
NCT06058793 2026-01-09

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Boehringer Ingelheim

Phase 3 Completed
138 enrolled
Sarcoma

Liposarcoma

NCT02451943 2025-07-15

ANNOUNCE

Eli Lilly and Company

Phase 3 Completed
509 enrolled 23 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT04979442 2025-01-14

MANTRA

Rain Oncology Inc

Phase 3 Terminated
175 enrolled 16 charts
Sarcoma

Liposarcoma, Sarcoma

NCT01692678 2018-07-11

A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma

Xian-Janssen Pharmaceutical Ltd.

Phase 3 Completed
16 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡